WADE HACHINSKY: Open Payments
NPI 1598744419 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,521 in 90 payments from 14 companies in 2025. Trend: 2023 $1,367 · 2024 $1,635 · 2025 $1,521
Food & beverage: $1,521
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $319 |
| ABBVIE INC. | 17 | $204 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 14 | $202 |
| Vanda Pharmaceuticals Inc. | 8 | $167 |
| E.R. Squibb & Sons, L.L.C. | 6 | $119 |
| Neurocrine BioSciences, Inc. | 5 | $106 |
| Lundbeck LLC | 4 | $87 |
| Axsome Therapeutics, Inc. | 5 | $87 |
| Collegium Pharmaceutical, Inc. | 4 | $73 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $60 |
Products named: REXULTI, VRAYLAR, CAPLYTA, HETLIOZ, ABILIFY ASIMTUFII, COBENFY, INGREZZA, Jornay PM.
Industry payments across KS — which companies pay providers there.
